|
A Randomized Phase II Trial of Weekly vs.. Every Two-Week vs.
Every Three-Week Administration of ABI-007 in Combination with
Bevacizumab in Women with Metastatic Breast Cancer
Patients must have pathologically confirmed adenocarcinoma of
the breast; Stage IV measurable disease; Must not be a candidate
for Herceptin therapy; Cannot be HER-2 positive or HER-2
unknown; Must be at least four weeks since radiotherapy
with full recovery: The measurable disease must be completely outside
the radiation portal or there must be pathologic proof of progression
disease within the radiation portal; Patients must be at least
four weeks from major surgery with full recover; ECOG performance
status 0-2; Female >18 years of age; Meet specific baseline
blood chemistry levels (refer to protocol); Negative pregnancy
test within 72 hours of first dose (if Applicable); Patients must
agree to use an effective method of birth control to avoid pregnancy
for the duration of the study; Must have a signed informed consent.
<< Back to Clinical
Trials Main Page >>
[ top ] |
